{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:43:40Z","timestamp":1782809020083,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10388-026-01207-1","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:49:02Z","timestamp":1776332942000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Japanese prospective registry study of particle therapy for esophageal cancer including comparison with clinical trials in Japan"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1158","authenticated-orcid":false,"given":"Takashi","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Isozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Takakusagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"10466","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang H, Wang F, Hallemeier CL, et al. Oesophageal cancer. Lancet. 2024;404(10466):1991\u20132005.","journal-title":"Lancet"},{"issue":"3","key":"1207_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1207_CR3","first-page":"656","volume":"21","author":"Y Teng","year":"2024","unstructured":"Teng Y, Xia C, Cao M, et al. Esophageal cancer global burden profiles, trends, and contributors. Cancer Biol Med. 2024;21(8):656\u201366.","journal-title":"Cancer Biol Med"},{"issue":"6","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ags3.12835","volume":"8","author":"T Higashi","year":"2024","unstructured":"Higashi T, Kurokawa Y. Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024. Ann Gastroenterol Surg. 2024;8(6):958\u201365.","journal-title":"Ann Gastroenterol Surg"},{"issue":"10","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004.","journal-title":"Ann Oncol"},{"issue":"3","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ueg2.12523","volume":"12","author":"R Porschen","year":"2024","unstructured":"Porschen R, Fischbach W, Gockel I, et al. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus. United Eur Gastroenterol J. 2024;12(3):399\u2013411.","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20(3):343\u201372.","journal-title":"Esophagus"},{"issue":"10447","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366.","journal-title":"Lancet"},{"issue":"6","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1053\/j.gastro.2021.08.007","volume":"161","author":"K Kato","year":"2021","unstructured":"Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology. 2021;161(6):1878-1886.e2.","journal-title":"Gastroenterology"},{"issue":"3","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","volume":"114","author":"H Takeuchi","year":"2022","unstructured":"Takeuchi H, Ito Y, Machida R, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114(3):454\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1207_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijrobp.2023.05.025","volume":"117","author":"M Pape","year":"2023","unstructured":"Pape M, Veen LM, Smit TM, et al. Late toxicity and health-related quality of life following definitive chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2023;117(1):31\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2006.09.7816","volume":"25","author":"D Schulz-Ertner","year":"2007","unstructured":"Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953\u201364.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jrr\/rrv001","volume":"56","author":"H Makishima","year":"2015","unstructured":"Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res. 2015;56(3):568\u201376.","journal-title":"J Radiat Res"},{"issue":"1","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13014-018-0966-5","volume":"13","author":"Y Hirano","year":"2018","unstructured":"Hirano Y, Onozawa M, Hojo H, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2018;13(1):23.","journal-title":"Radiat Oncol"},{"key":"1207_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpt.2024.100010","volume":"11","author":"M Sasaki","year":"2024","unstructured":"Sasaki M, Tamamura H, Tameshige Y, et al. Dose evaluation in 2-phase method for advanced esophageal cancer by hybrid irradiation techniques. Int J Part Ther. 2024;11:100010.","journal-title":"Int J Part Ther"},{"issue":"14","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1200\/JCO.19.02503","volume":"38","author":"SH Lin","year":"2020","unstructured":"Lin SH, Hobbs BP, Verma V, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020;38(14):1569\u201379.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijrobp.2017.06.2450","volume":"99","author":"M Xi","year":"2017","unstructured":"Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;99(3):667\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1207_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28136","volume":"6","author":"P Zhou","year":"2023","unstructured":"Zhou P, Du Y, Zhang Y, et al. Efficacy and safety in proton therapy and photon therapy for patients with esophageal cancer: a meta-analysis. JAMA Netw Open. 2023;6(8):e2328136.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1207_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070993","volume":"11","author":"T Ono","year":"2019","unstructured":"Ono T, Wada H, Ishikawa H, et al. Clinical results of proton beam therapy for esophageal cancer: multicenter retrospective study in Japan. Cancers (Basel). 2019;11(7):993.","journal-title":"Cancers (Basel)"},{"issue":"Supplement_1","key":"1207_CR20","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/jrr\/rrad012","volume":"64","author":"S Tokumaru","year":"2023","unstructured":"Tokumaru S, Ishikawa H, Soejima T, et al. Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer. J Radiat Res. 2023;64(Supplement_1):i16\u201324.","journal-title":"J Radiat Res"},{"key":"1207_CR21","volume-title":"TNM Classification of Malignant Tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th ed. Chichester: Wiley-Blackwell; 2009.","edition":"7th ed"},{"key":"1207_CR22","unstructured":"Japanese Society for Radiation Oncology. Unified Treatment Policy for each Disease of Particle Therapy. https:\/\/www.jastro.or.jp\/medicalpersonnel\/particle_beam\/pdf\/2022\/y_9.pdf, https:\/\/www.jastro.or.jp\/medicalpersonnel\/particle_beam\/pdf\/2022\/j_3.pdf (20 November 2022, date last accessed)(in Japanese)."},{"key":"1207_CR23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 Published: November 27, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50(17 September 2022, date last accessed)."},{"key":"1207_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/9780470258019","volume-title":"Applied Survival Analysis: Regression Modeling of Time-to-Event Data","author":"DW Hosmer","year":"2008","unstructured":"Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. 2nd ed. Hoboken: John Wiley & Sons Inc; 2008.","edition":"2nd ed"},{"issue":"12","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.3390\/cancers14123024","volume":"14","author":"D Dai","year":"2022","unstructured":"Dai D, Tian Q, Yu G, et al. Severe radiation-induced lymphopenia affects the outcomes of esophageal cancer: A comprehensive systematic review and meta-analysis. Cancers (Basel). 2022;14(12):3024.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1207_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2023.08.058","volume":"118","author":"X Wang","year":"2024","unstructured":"Wang X, van Rossum PSN, Chu Y, et al. Severe lymphopenia during chemoradiation therapy for esophageal cancer: Comprehensive analysis of randomized phase 2B trial of proton beam therapy versus intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2024;118(2):368\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1207_CR27","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.jtho.2020.06.014","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, Palaskas NL, Yusuf SW, et al. Incidence and onset of severe cardiac events after radiotherapy for esophageal cancer. J Thorac Oncol. 2020;15(10):1682\u201390.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1207_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s10388-020-00794-x","volume":"18","author":"M Takahashi","year":"2021","unstructured":"Takahashi M, Kato K, Okada M, et al. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). Esophagus. 2021;18(1):90\u20139.","journal-title":"Esophagus"},{"issue":"1","key":"1207_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10388-021-00877-3","volume":"19","author":"K Muro","year":"2022","unstructured":"Muro K, Kojima T, Moriwaki T, et al. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus. 2022;19(1):137\u201345.","journal-title":"Esophagus"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01207-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:45:05Z","timestamp":1782805505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-026-01207-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s10388-026-01207-1","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Takayuki Hashimoto received a research grant from\u00a0AMED under grant JP16lm0103004. Hideyuki Sakurai was outside director in B dot Medical Inc. Ltd, and had other financial or non-financial interests in Hitachi High-Tech Corporatio Collaborative research. The other authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}